Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder

Cutler, Andrew J.; Montgomery, Stuart; Feifel, David; Lazarus, Arthur; Åström, Mikael; Brecher, Martin

doi:10.4088/jcp.08m04592

Cited by 126 publications

(136 citation statements)

References 44 publications

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…Significantly, quetiapine, with a structure similar to clozapine and olanzapine, has an active metabolite, norquetiapine, which is a potent NET inhibitor that has been identified and visualized in the primate brain (Nyberg et al, 2007). Thus, the recently shown antidepressant effect of quetiapine (Bandelow et al, 2010;Bauer et al, 2009;Cutler et al, 2009), as well as its utility in bipolar depression may be related to concomitant NET inhibition in combination with a low D 2 occupancy (Kessler et al, 2006). Finally, clinical data indicate that adding a NET inhibitor such as reboxetine to olanzapine in the treatment of schizophrenia attenuates the olanzapine-induced weight gain (Poyurovsky et al, 2003(Poyurovsky et al, , 2007.…”

Section: Discussionmentioning

confidence: 99%

Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

Marcus¹,

Jardemark²,

Malmerfelt³

et al. 2010

Neuropsychopharmacol

View full text Add to dashboard Cite

Preclinical data have shown that addition of the selective norepinephrine transporter (NET) inhibitor reboxetine increases the antipsychotic-like effect of the D 2/3 antagonist raclopride and, in parallel, enhances cortical dopamine output. Subsequent clinical results suggested that adding reboxetine to stable treatments with various antipsychotic drugs (APDs) may improve positive, negative and depressive symptoms in schizophrenia. In this study, we investigated in rats the effects of adding reboxetine to the second-generation APD olanzapine on: (i) antipsychotic efficacy, using the conditioned avoidance response (CAR) test, (ii) extrapyramidal side effect (EPS) liability, using a catalepsy test, (iii) dopamine efflux in the medial prefrontal cortex and the nucleus accumbens, using in vivo microdialysis in freely moving animals and (iv) cortical N-methyl-D-aspartate (NMDA) receptor-mediated transmission, using intracellular electrophysiological recording in vitro. Reboxetine (6 mg/kg) enhanced the suppression of CAR induced by a suboptimal dose (1.25 mg/kg), but not an optimal (2.5 mg/kg) dose of olanzapine without any concomitant catalepsy. Addition of reboxetine to the low dose of olanzapine also markedly increased cortical dopamine outflow and facilitated prefrontal NMDA receptor-mediated transmission. Our data suggest that adjunctive treatment with a NET inhibitor may enhance the therapeutic effect of low-dose olanzapine in schizophrenia without increasing EPS liability and add an antidepressant action, thus in principle allowing for a dose reduction of olanzapine with a concomitant reduction of dose-related side effects, such as EPS and weight gain.

show abstract

Section: Discussionmentioning

confidence: 99%

Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

Marcus¹,

Jardemark²,

Malmerfelt³

et al. 2010

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…The only direct comparison with an antidepressant was with duloxetine, which may be less effective and less tolerable than other antidepressants; 22 that study found no differences in efficacy between treatment and control groups, but overall tolerability was reduced among those taking quetiapine. 23 The extent of quetiapine use to treat anxiety is unprecedented for an antipsychotic. Although several small randomized trials 24,25 were completed and published earlier, the first large randomized controlled trial (RCT) of quetiapine for anxiety was published in a peer-reviewed journal in 2010 26 followed by 4 others [27][28][29][30] in the following years.…”

Section: Discussionmentioning

confidence: 99%

Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study

Pringsheim

Gardner

2014

CMAJ Open

View full text Add to dashboard Cite

“…[9][10][11] Patients with MDD and bipolar disorder frequently experience sleep disturbances. 12 Poor sleep quality and/or quantity are observed in up to 90% of depressed patients.…”

mentioning

confidence: 99%

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression

Gedge

Lazowski²,

Murray³

et al. 2010

NDT

View full text Add to dashboard Cite

Objective:To determine the effect of adjunctive quetiapine therapy on the sleep architecture of patients with bipolar or unipolar depression. Methods: This is a prospective, single-blind, repeated measures polysomnographic study. Sleep architecture was analyzed by overnight polysomnography, and subjective sleep quality was measured using the Pittsburgh Sleep Quality Index. The Hamilton Rating Scale for Depression, Montgomery Asberg Depression Rating Scale, Young Mania Rating Scale, and Clinical Global Impression-Severity Scale were employed to quantify changes in illness severity with adjunctive quetiapine treatment. Polysomnographs and clinical measures were administered at baseline, after 2-4 days of treatment, and after 21-28 days of quetiapine treatment. The average dose of quetiapine was 155 mg, ranging from 100-200 mg. Results: Adjunctive quetiapine therapy did not significantly alter sleep efficiency, sleep continuity, or Pittsburgh Sleep Quality Index scores. Respiratory Disturbance Index and percentage of total time in rapid eye movement (REM) sleep significantly decreased and the percentage of total time in non-REM sleep, and duration of Stage 2 and non-REM sleep significantly increased after 2-4 days of quetiapine treatment. Illness severity significantly decreased over time. Conclusions: Adjunctive quetiapine treatment alters sleep architecture in patients with major depressive disorder or bipolar disorder, which may partially explain its early antidepressant properties. Changes in sleep architecture are more robust and significant within two to four days of starting treatment.

show abstract

Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder

Cited by 126 publications

References 44 publications

Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission

Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression

Contact Info

Product

Resources

About